Haloperidol Richter

Haloperidol Richter is a prescription medication that contains the active ingredient haloperidol, a typical antipsychotic of the butyrophenone class. It is supplied in oral dosage form, with strength and specific formulation determined by the manufacturer for the European market. Haloperidol works as a dopamine D2 receptor antagonist and is used under medical supervision for several psychiatric conditions. The product is regulated as a prescription‑only drug in the EU.

Haloperidol Richter is indicated for the management of several acute and chronic psychiatric disorders where dopamine blockade is therapeutic.

- Schizophrenia, including maintenance therapy. - Acute psychotic episodes or exacerbations. - Severe agitation requiring rapid control. - Tourette syndrome with motor and vocal tics. - Short‑term treatment of acute mania when clinically appropriate.

Side effects of haloperidol may vary in frequency and severity; they are typically categorized as common or serious.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Dry mouth. - Constipation. - Blurred vision.

Serious: - Neuroleptic malignant syndrome. - Cardiac arrhythmias, including QT prolongation and torsades de pointes. - Severe hypotension. - Elevated prolactin levels leading to galactorrhea or menstrual disturbances.

When prescribing Haloperidol Richter, clinicians consider several precautionary measures to minimize risks and ensure appropriate use.

- Assess patient history for cardiovascular disease, especially conditions that predispose to QT prolongation. - Evaluate for existing movement disorders or Parkinsonian features before initiating therapy. - Use the lowest effective dose, particularly in elderly patients, to reduce sedation and fall risk. - Monitor for signs of neuroleptic malignant syndrome throughout treatment. - Consider pregnancy and lactation status; haloperidol is classified as pregnancy category unknown and should be used only if benefits outweigh potential risks. - Review hepatic and renal function periodically to adjust dosing if necessary.

Haloperidol can interact with other medications, influencing its efficacy or safety profile.

Avoid: - Concurrent use with other dopamine antagonists or antipsychotics, which may increase extrapyramidal risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol plasma concentrations. - QT‑prolonging agents such as quinidine, sotalol, or certain antiemetics, increasing the risk of cardiac arrhythmias.

Use with caution: - Central nervous system depressants (e.g., benzodiazepines, opioids) that may enhance sedation. - Anticholinergic drugs, which can mask extrapyramidal symptoms. - Lithium, as combined therapy may increase neurotoxicity.